Results 151 to 160 of about 92,748 (341)

MEFV gene mutation analysis in patient with PFAPA [PDF]

Introduction : syndrome PFAPA (periodic fever, aphthous mouth, pharyngitis and adenitis) is a clinical syndrome that usually occur in children younger than 5 years.
حسینی اصل, سید سعید, صالح زاده, فرهاد, واحدی نمین, مریم   +2 more
core   +1 more source

The perception of palpitations and its risk factors among general population in the western region of Saudi Arabia: A cross-sectional study [PDF]

, 2023
Majid H Ali, Mohammad H Baharith, Raneem A Alahmadi, Osama S Zamzami, Omniyyah Tukruni, Majd A Almuqati, Sayed A Tabriz   +6 more
openalex   +1 more source

Safety and Efficacy of Pulsed Field Ablation for Atrial Fibrillation in Elderly Patients

Journal of Arrhythmia, Volume 42, Issue 1, February 2026.
Pulsed‐field ablation (PFA) was evaluated in 479 patients with atrial fibrillation (AF), 52% paroxysmal. Among 104 patients > 75 years, complication rates and 6‐ and 12‐month arrhythmia‐free survival were not significantly different from younger patients. Age did not predict recurrence. PFA appears safe and effective in elderly AF patients.
Federico Follesa, Alix Prévot, Samy Gribissa, Xavier Waintraub, Marine Thuillot, Nicolas Badenco, Guillaume Duthoit, Estelle Gandjbakhch, Mikael Laredo   +8 more
wiley   +1 more source

Promoting child development [PDF]

, 2012
Puras, D, Rechel, B
core   +2 more sources

Septic Shock Caused by Coinfection of Shewanella algae Bloodstream Infection and Epstein‐Barr Virus: Clinical Characteristics and Genomic Analysis

MicrobiologyOpen, Volume 15, Issue 1, February 2026.
This study reports a septic shock case in inland China caused by coinfection of Shewanella algae bloodstream infection and Epstein‐Barr virus. Genomic analysis revealed freshwater adaptation of the strain via unique genes for transporters and carbohydrate‐active enzymes.
Jianmei Chen, Dong Ling, Feng Wang, Liping Liu, Yucheng Ren, Chengying Chen, Na Su   +6 more
wiley   +1 more source

Pharmacometric‐Based Evaluation of Salmeterol and Its Metabolite α‐Hydroxysalmeterol in Plasma and Urine: Practical Implications for Doping Control

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.
ABSTRACT Salmeterol is a commonly used β2‐agonist included on the List of Prohibited Substances and Methods published by the World Anti‐Doping Agency (WADA). We developed a population pharmacokinetic (popPK) model to describe the PK of salmeterol including its major metabolite, α‐hydroxysalmeterol, in plasma and urine after inhalation.
Paul Thoueille, Anne Danion, Morten Hostrup, Michael Petrou, Koen Deventer, Thierry Buclin, François R. Girardin, Irene Mazzoni, Olivier Rabin, Monia Guidi   +9 more
wiley   +1 more source

Management of Ablation-Refractory Atrial Fibrillation During Pregnancy. [PDF]

Case Rep Med
Development of new atrial fibrillation (AF) is uncommon in pregnancy with an incidence of 0.03%. The occurrence of drug‐refractory AF during pregnancy in individuals with structurally normal hearts is even rarer, and there are no reports of ablation‐refractory AF during pregnancy in the literature.
Abu Za'nouneh F, Benavente K, Neuendorf J, Kadomoto B, Chong C.   +4 more
europepmc   +2 more sources

Greetings from below the aortic arch! The paradigm of cardiac paraganglioma. [PDF]

, 1996
Heufelder, Armin E., Hofbauer, Lorenz C.
core   +1 more source

Effects of likelihood framing on side effect expectations and nocebo side effects: Results from three experimental studies with a placebo analgesic cream

British Journal of Health Psychology, Volume 31, Issue 1, February 2026.
Abstract Objectives This research examined whether different framings of the likelihood of side effects influence their occurrence in response to a placebo analgesic. Design Three independent experimental studies in non‐clinical samples were performed.
Tobias Kube, John M. Kelley, Arthur J. Barsky, Julia A. Glombiewski   +3 more
wiley   +1 more source

Impact of Prior Intravenous Immunoglobulin and Plasmapheresis on Eculizumab or Ravulizumab Treatment for Generalized Myasthenia Gravis: An Analysis of the MG SPOTLIGHT Registry

Clinical and Experimental Neuroimmunology, Volume 17, Issue 1, February 2026.
ABSTRACT Objective The complement component 5 inhibitor therapies (C5ITs) eculizumab and ravulizumab are approved for the treatment of generalized myasthenia gravis (gMG). We evaluated the real‐world effectiveness and safety of eculizumab and ravulizumab in patients with gMG with or without prior intravenous immunoglobulin (IVIg) or plasma exchange ...
Akiyuki Uzawa, Ema Rodrigues, Hiroyuki Murai   +2 more
wiley   +1 more source